title: Spindle cell squamous cell carcinoma arising from verrucous hyperplasia during BRAF inhibitor therapy for melanoma.
authors.affiliation: University Hospital Leipzig, Department of Dermatology, Venereology and Allergology.
authors.forename: Mirjana
authors.initials: M
authors.lastname: Ziemer
authors.forename: Iris
authors.initials: I
authors.lastname: Pönitzsch
authors.forename: Jan Christoph
authors.initials: JC
authors.lastname: Simon
authors.forename: Monica
authors.initials: M
authors.lastname: Schüürmann
mesh_terms: D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018289:Carcinoma, Verrucous / Q000139:chemically induced* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012509:Sarcoma / Q000139:chemically induced* / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf